Sanofi (NASDAQ:SNY) Shares Bought by Regal Partners Ltd

Key Points

• Regal Partners Ltd increased its stake in Sanofi by 5.4%, owning a total of 765,366 shares valued at approximately $42.4 million, making it the firm's 9th largest position.
• Sanofi's recent earnings report indicated a missed EPS estimate of $0.90 compared to a consensus of $0.96, while revenue outperformed expectations at $11.34 billion.
• Multiple equity research analysts have given Sanofi a consensus rating of "Buy", with a target price of $62.00, showcasing positive market sentiment towards the company's stock.

Regal Partners Ltd grew its holdings in Sanofi (NASDAQ:SNY - Free Report) by 5.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 765,366 shares of the company's stock after purchasing an additional 38,981 shares during the quarter. Sanofi comprises 4.3% of Regal Partners Ltd's portfolio, making the stock its 9th biggest holding. Regal Partners Ltd's holdings in Sanofi were worth $42,447,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Cardinal Capital Management raised its stake in shares of Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after acquiring an additional 199 shares during the last quarter. Gradient Investments LLC raised its stake in shares of Sanofi by 2.1% in the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock valued at $542,000 after acquiring an additional 200 shares during the last quarter. Perigon Wealth Management LLC raised its stake in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after acquiring an additional 201 shares during the last quarter. Beacon Financial Group raised its stake in shares of Sanofi by 1.6% in the first quarter. Beacon Financial Group now owns 14,398 shares of the company's stock valued at $799,000 after acquiring an additional 222 shares during the last quarter. Finally, AdvisorNet Financial Inc raised its stake in shares of Sanofi by 16.4% in the first quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company's stock valued at $89,000 after acquiring an additional 227 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Up 1.5%

SNY traded up $0.73 during trading on Friday, reaching $49.77. 2,021,563 shares of the company's stock were exchanged, compared to its average volume of 2,577,324. The company's fifty day moving average price is $48.58 and its 200-day moving average price is $51.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12. The firm has a market capitalization of $122.21 billion, a PE ratio of 11.96, a P/E/G ratio of 1.16 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%. The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period in the prior year, the firm posted $1.73 EPS. Sanofi's revenue was down 7.0% on a year-over-year basis. As a group, equities analysts forecast that Sanofi will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on SNY shares. Barclays restated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Finally, Morgan Stanley set a $56.00 price objective on shares of Sanofi in a research report on Monday, June 2nd. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Sanofi presently has an average rating of "Buy" and an average price target of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.